相关实验视频

Updated: May 5, 2026

Expression of Recombinant Proteins in the Methylotrophic Yeast Pichia pastoris

Expression of Recombinant Proteins in the Methylotrophic Yeast Pichia pastoris

Published on: February 25, 2010

在Pichia pastoris中开发一个重组的Omicron BA.1亚单元候选疫苗

Sibel Kalyoncu¹, Dogu Sayili¹, Ayca Zeybek Kuyucu¹

¹Izmir Biomedicine and Genome Center, Izmir, Turkey.

Microbial biotechnology

|January 16, 2025

概括

一种基于SARS-CoV-2 Omicron BA.1变异的新复合疫苗候选人,表达在Pichia pastoris中,显示出高抗原性和广泛的抗体识别对多种变异. 这种低成本的候选疫苗在小鼠中引起了强烈的,持久的免疫反应,适合未来的流行病准备.

科学领域:

疫苗学疫苗学疫苗学
蛋白质表达方式
免疫学免疫学免疫学

背景情况:

需要低成本,安全的疫苗来解决全球疫苗不平等对未来的流行病至关重要.
皮奇亚牧草提供了一个具有成本效益和可扩展的系统,用于重组蛋白质的生产,使其适合疫苗开发.

研究的目的:

开发一种基于Pichia pastoris表达系统的下一代SARS-CoV-2 Omicron BA.1复合疫苗候选人.
评估这种候选疫苗对各种SARS-CoV-2变种的免疫性和保护潜力.

主要方法:

再组合的奥米克朗BA.1受体结合域 (RBD-Omicron) 在P. pastoris表达并净化.
试验室表征包括染色学,质谱学,热量计和表面等离子体共振.
在小鼠中进行了免疫研究,使用不同剂量的RBD-Omicron与和CpG辅助剂.

主要成果:

在净化后,RBD-Omicron的高产量 (0.35g/L) 和纯度 (99%) 得到了实现.
辅助RBD-Omicron的10微克剂量显示出最高的抗原性.
接种疫苗诱导的IgG标位超过10^6和对Delta Plus,Eris和Pirola变种的交叉反应.
显著的IgG标位和Th1T细胞反应在小鼠中维持了60周以上.

结论:

Pichia pastoris表达的RBD-Omicron疫苗候选人具有高度免疫性,并引起持久的跨变体免疫反应.
这种候选疫苗显示出应对未来流行病威胁的希望,特别是那些由Omicron亚型驱动的疫苗.
开发的疫苗适合技术转让和临床进展.

关键词:

这就是Pichia pastoris.这是COVID-19疫苗.在SARS-CoV-2中.奥米克朗 BA.1 的情况.复合蛋白子单元疫苗的疫苗.

更多相关视频

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

相关概念视频

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...